Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging (Q36109265)

12 August 2017

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging (English)

1 reference

triple-negative breast cancer

12 August 2017

1 reference

Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography

inferred from title

1 reference

Yong Yue

1

1 reference

12 August 2017

Xiaojiang Cui

2

1 reference

12 August 2017

Shikha Bose

3

1 reference

12 August 2017

William Audeh

4

1 reference

12 August 2017

Xiao Zhang

5

1 reference

12 August 2017

Benedick Fraass

6

1 reference

12 August 2017

language of work or name

English

0 references

publication date

7 September 2015

1 reference

Breast Cancer Research and Treatment

12 August 2017

1 reference

12 August 2017

153

1 reference

12 August 2017

3

1 reference

12 August 2017

607-616

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

12 August 2017

start time

7 September 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Tackling the diversity of triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Supervised risk predictor of breast cancer based on intrinsic subtypes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Molecular portraits of human breast tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Predicting pathological complete response in breast cancer early.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Challenges translating breast cancer gene signatures into the clinic

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589560

18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10549-015-3558-1

New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma

21 January 2018

1 reference

12 December 2020

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

12 December 2020

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

1 reference

12 December 2020

Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis

1 reference

12 December 2020

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

12 December 2020

10.1007/S10549-015-3558-1

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

26346756

1 reference